Daratumumab (Anti-CD38)
Based on 13 publication(s) in Google Scholar
Daratumumab (Anti-CD38) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (Anti-CD38) has anti-multiple myeloma (MM) effect. Daratumumab (Anti-CD38) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 97.94%
- No. CAS: 945721-28-8
- Peso molecular:145.26 kDa
-
Almacenamiento:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
Descripciòn
IC50 & Target
CD38
In Vitro
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Aplicación
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow Cytometry analysis of Raji cells labelling CD38 (red) with Daratumumab (anti-CD38) (HY-P9915A). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Product Details
-
No. CAS 945721-28-8
-
Accession P28907
-
Synonyms Anti-Human CD38, Human Antibody (PBS)
-
Peso molecular 145.26 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 kappa
-
Recommend Isotype Controls
-
Format
-
Human IgG1 kappa
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Pureza
97.94%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Envío
Shipping with dry ice.
Publications (13)
-
Journal Impact Factor
-
Most Recent
-
Nat Biotechnol
2025 Oct 17. PMID: 41107533
Daratumumab (Anti-CD38) purchased from MedChemExpress. Usage Cited in: Nat Biotechnol. 2025 Oct 17. [Abstract]
A single mesodermal tumor was injected into mesodermal CAR-T cells, and the following treatments were administered: untreated group, daratumumab (0.5 or 10 μg/ml) treatment group, or IgG isotype control antibody (10 μg/ml IgG) treatment group. The change in T cell area over time was quantitatively analyzed.
-
Nat Commun
CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRPα-CD47 to suppress tumor growth. [Abstract]2025 Jun 3;16(1):5145. PMID: 40461553 -
Clin Cancer Res
Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma. [Abstract]2023 Aug 15;29(16):2988-3003. PMID: 37265425
Daratumumab (Anti-CD38) purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2023 Aug 15;29(16):2988-3003. [Abstract]
ADCC capability of INBRX-109 was evaluated in the Promega Jurkat CD16a (V158) ADCC reporter assay using DR5-transfected ExpiCHO-S cells as targets and untransfected cells as negative controls. Daratumumab (5.5 h), the target of which is expressed on Jurkat cells, serves as a positive control.
Daratumumab (Anti-CD38) purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2023 Aug 15;29(16):2988-3003. [Abstract]
The ability of INBRX-109 to bind the complement component C1q contained within normal human serum was measured by ELISA. Daratumumab (5.5 h) is used as a positive control.
-
J Med Chem
CD38-Targeted Small-Molecule PET Radiotracer for Noninvasive Tumor Evaluation and Preliminary Therapy Monitoring in Multiple Myeloma. [Abstract]2026 Mar 26;69(6):7068-7081. PMID: 41837524 -
Cell Mol Life Sci
Reduced ALDH1A1 expression in multiple myeloma cells increases resistance to daratumumab via downregulation of retinoic acid. [Abstract]2025 Oct 7;82(1):352. PMID: 41055748
Daratumumab (Anti-CD38) purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2025 Oct 7;82(1):352. [Abstract]
ADCC in H929 cells caused by various concentration of Dara (Daratumumab, 1h treatment and 4h NK cell co-culture).
Daratumumab (Anti-CD38) purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2025 Oct 7;82(1):352. [Abstract]
Compared with vehicle control, Dara (Daratumumab, i.p. 8 mg/kg per mouse weekly for 3w) cause significantly reduction of xenograft tumors weight and tumor growth.
Daratumumab (Anti-CD38) purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2025 Oct 7;82(1):352. [Abstract]
Inhibitor of ALDH1A 673 A remarkably reduce the protein level of CD38, ALDH1A1 and RAR, and RA complement significantly restore the protein level of CD38 and RAR. Dara (Daratumumab, i.p. 8 mg/kg per mouse weekly for 3w).
-
-
Bioconjug Chem
Resin-Supported Site-Specific Antibody Conjugation Method Leads to Antibody-Drug Conjugates with Retained Efficacy and Improved Stability. [Abstract]2025 Aug 21. PMID: 40839643 -
Electrophoresis
A Separation Buffers Platform Set to Facilitate CZE Charge Heterogeneity Method Development for Monoclonal Antibodies. [Abstract]2026 Mar 24. PMID: 41873887 -
Transfus Med
Antigen masking indirect antiglobulin test can mitigate the interference of Mezagitamab, a novel anti-CD38 antibody, in serological pre-transfusion testing. [Abstract]2025 Apr 9. PMID: 40204650 -
-
Blood Neoplasia
Bone marrow immune cell composition reflects multiple myeloma progression and affects treatment response. [Abstract]2025 Oct 16;3(1):100174. PMID: 41480309 -
-
Pureza y Documentación
Referencias
[1]. Ghose J, Viola D, et al. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology. 2018;7(10):e1486948. Published 2018 Jul 23. [Content Brief]
[2]. de Weers M, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840-1848. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)